Compritol^®-based solid lipid nanoparticles of desvenlafaxine prepared by ultrasonication-assisted hot-melt encapsulation to modify its release

References

• Maeda H. Research spotlight: emergence of EPR effect theory and development of clinical applications for cancer therapy. Ther. Deliv. 5(6), 627–630 (2014).
   PubMedGoogle Scholar
• Qushawy M, Nasr A, Abd-Alhaseeb M, Swidan S. Design solid lipid nanoparticles (SLNs) as nano drug delivery carriers: preparation, characterization, and application. Int. J. Appl. Pharm. 12(1), 1–9 (2020).
   Google Scholar
• Shinde RB, Hosmani AH, Shende MA, Jarag RJ, Thorat YS. Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug darunavir. Appl. Nanosci. 7(1–2), 47–57 (2017).
   Web of Science ®Google Scholar
• Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Rel. 127(2), 97–109 (2008).
   PubMed Web of Science ®Google Scholar
• Shah M, Agrawal YK, Garala K, Ramkishan A. Solid lipid nanoparticles of a water soluble drug, ciprofloxacin hydrochloride. Indian J. Pharm. Sci. 74(5), 434 (2012).
   PubMed Web of Science ®Google Scholar
• Tong GF, Qin N, Sun LW. Development and evaluation of desvenlafaxine loaded PLGA–chitosan nanoparticles for brain delivery. Saudi Pharm. J. 25(6), 844–851 (2017).
   PubMed Web of Science ®Google Scholar
• Samy W, Elnoby A, El-Gowelli HM, Elgindy N. Hybrid polymeric matrices for oral modified release of desvenlafaxine succinate tablets. Saudi Pharm. J. 25(5), 676–687 (2017).
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Shukla D, Mishra B, Singh S. Lipid – an emerging platform for oral delivery of drugs with poor bioavailability. Eur. J. Pharm. Biopharm. 73(1), 1–15 (2009).
   PubMed Web of Science ®Google Scholar
• Keck C, Ruick R, Müller R. The smartLipids®-3rd generation of lipid nanoparticles after SLN® and NLC® in Controlled Release Society annual meeting. Pharmazie 72(12), 728–735 (2015).
   Google Scholar
• Jaspart S, Piel G, Delattre L, Evrard B. Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications. Expert Opin. Drug Deliv. 2(1), 75–87 (2005).
   PubMedGoogle Scholar
• Souto EB, Almeida AJ, Müller RH. Lipid nanoparticles (SLN®, NLC®) for cutaneous drug delivery: structure, protection and skin effects. J. Biomed. Nanotechnol. 3(4), 317–331 (2007).
   Web of Science ®Google Scholar
• Rao H, Ahmad S, Madni A et al. Compritol-based alprazolam solid lipid nanoparticles for sustained release of alprazolam: preparation by hot melt encapsulation. Molecules 27(24), 8894 (2022).
   PubMed Web of Science ®Google Scholar
• Emami J, Yousefian H, Sadeghi H. Targeted nanostructured lipid carrier for brain delivery of artemisinin: design, preparation, characterization, optimization and cell toxicity. J. Pharm. Sci. 21(Suppl. 1), S225–S241 (2018).
   Web of Science ®Google Scholar
• Rao H, Ahmad S, Madni A, Ahmad I, Shahzad MN. Single-step extraction for simultaneous quantification of desvenlafaxine and alprazolam in human spiked plasma by RP-HPLC. PLOS ONE 15(9), e0238954 (2020).
   PubMed Web of Science ®Google Scholar
• Aslam M, Aqil M, Ahad A et al. Application of Box–Behnken design for preparation of glibenclamide loaded lipid based nanoparticles: optimization, in vitro skin permeation, drug release and in vivo pharmacokinetic study. J. Mol. Liq. 219, 897–908 (2016).
   Web of Science ®Google Scholar
• Shukla S, Kumar P, Moorthy NS, Shrivastava SK, Trivedi P, Srivastava RS. RP-HPLC method development and its validation for simultaneous estimation of alprazolam and fluoxetine hydrochloride in pharmaceutical dosage form. Eur. J. Anal. Chem. 5(3), 239–245 (2010).
   Google Scholar
• Chawla V, Saraf SA. Glyceryl behenate and its suitability for production of aceclofenac solid lipid nanoparticles. JAOCS 88(1), 119–126 (2011).
   Web of Science ®Google Scholar
• Aburahma MH, Badr-Eldin SM. Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals. Expert Opin. Drug Deliv. 11(12), 1865–1883 (2014).
   PubMed Web of Science ®Google Scholar
• Sivadasan D, Ramakrishnan K, Mahendran J, Ranganathan H, Karuppaiah A, Rahman H. Solid lipid nanoparticles: applications and prospects in cancer treatment. Int. J. Mol. Sci. 24(7), 6199 (2023).
   PubMed Web of Science ®Google Scholar
• Javed S, Mangla B, Almoshari Y, Sultan MH, Ahsan W. Nanostructured lipid carrier system: a compendium of their formulation development approaches, optimization strategies by quality by design, and recent applications in drug delivery. Nanotechnol. Rev. 11(1), 1744–1777 (2022).
   Web of Science ®Google Scholar
• Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J. Pharm. Pharmacol. 56(12), 1527–1535 (2004).
   PubMed Web of Science ®Google Scholar
• Jana S, Maji N, Nayak AK, Sen KK, Basu SK. Development of chitosan-based nanoparticles through inter-polymeric complexation for oral drug delivery. Carbohydr. Polym. 98(1), 870–876 (2013).
   PubMed Web of Science ®Google Scholar
• Najib Ullah SN, Afzal O, Altamimi AS et al. Bedaquiline-loaded solid lipid nanoparticles drug delivery in the management of non-small-cell lung cancer (NSCLC). Pharmaceuticals 16(9), 1309 (2023).
   Web of Science ®Google Scholar
• Mudalige T, Qu H, Van Haute D, Ansar SM, Paredes A, Ingle T. Characterization of nanomaterials: tools and challenges, in nanomaterials for food applications. In: Nanomaterials for Food Applications Elsevier Inc., MA, USA, 313–353 (2019).
   Google Scholar
• Rahmanian-Devin P, Askari VR, Sanei-Far Z et al. Preparation and characterization of solid lipid nanoparticles encapsulated noscapine and evaluation of its protective effects against imiquimod-induced psoriasis-like skin lesions. Biomed. Pharmacother. 168, 115823 (2023).
   PubMed Web of Science ®Google Scholar
• Alex A, Paul W, Chacko AJ, Sharma CP. Enhanced delivery of lopinavir to the CNS using Compritol®-based solid lipid nanoparticles. Ther. Deliv. 2(1), 25–35 (2011).
   PubMedGoogle Scholar
• Müller RH, Runge SA, Ravelli V, Thünemann AF, Mehnert W, Souto EB. Cyclosporine-loaded solid lipid nanoparticles (SLN®): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 68(3), 535–544 (2008).
   PubMed Web of Science ®Google Scholar
• Duan Y, Dhar A, Patel C et al. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Adv. 10(45), 26777–26791 (2020).
   PubMed Web of Science ®Google Scholar
• Da Silva JD, de Sousa VP, Cabral LM et al. In vitro–in vivo correlation for desvenlafaxine succinate monohydrate extended release tablets. AAPS PharmSciTech 21(5), 1–9 (2020).
   Web of Science ®Google Scholar
• Barzegar-Jalali M. Kinetic analysis of drug release from nanoparticles. J. Pharm. Sci. 11(1), 167–177 (2008).
   Web of Science ®Google Scholar
• Hogarth C, Arnold K, Wright S, Elkateb H, Rannard S, McDonald TO. Navigating the challenges of lipid nanoparticle formulation: the role of unpegylated lipid surfactants in enhancing drug loading and stability. Nanoscal. Adv. 6(7), 669–679 (2024).
   PubMedGoogle Scholar
• Dugad T, Kanugo A. Design optimization and evaluation of solid lipid nanoparticles of azelnidipine for the treatment of hypertension. Recent Pat. Nanotechnol. 18(1), 22–32 (2024).
   Web of Science ®Google Scholar
• Pareek A, Kothari R, Pareek A et al. Development of a new inhaled swellable microsphere system for the dual delivery of naringenin-loaded solid lipid nanoparticles and doxofylline for the treatment of asthma. Eur. J. Pharm. Sci. 193, 106642 (2024).
   PubMed Web of Science ®Google Scholar
• Khan A, Pawar V, Bagale R, Pendse S, Adapa A. Solid lipid nanoparticles: towards emerging cancer nanomedicine. In: Nanomaterials in Healthcare. CRC Press, Boca Raton, FL, USA, 281–296 (2024).
   Google Scholar